Aarti Drugs AARTIDRUGS
High-volume API maker (metformin, ciprofloxacin, antifungals) backward-integrated into its own intermediates
Mapped in 1 theme: Pharmaceuticals.
Where Aarti Drugs sits in the supply chain
Aarti Drugs appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › APIs (active ingredients)
Direct supplierOther companies in this layer
Pharmaceuticals › KSMs & intermediates
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 2,529 | 2,387 | 2,565 |
| Net profit | 172 | 168 | 195 |
Latest-year revenue ₹2,565 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Backward integration into intermediates lowers China dependence
- Lower valuation than most API peers
Risks
- Commodity APIs directly exposed to Chinese price competition - revenue flat FY22-FY26
- Thin margins, and the stock has fallen in the year to Oct 2026
Common questions
What does Aarti Drugs do?
High-volume API maker (metformin, ciprofloxacin, antifungals) backward-integrated into its own intermediates.
Where does Aarti Drugs sit in the supply chain?
Aarti Drugs (NSE: AARTIDRUGS) is mapped in 2 supply-chain layers: APIs (active ingredients) (Pharmaceuticals) and KSMs & intermediates (Pharmaceuticals).
Who are Aarti Drugs' peers?
In the APIs (active ingredients) layer of Pharmaceuticals: Divi's Laboratories, Laurus Labs, Solara Active Pharma Sciences, Concord Biotech, Granules India, Neuland Laboratories and 2 more.
What is Aarti Drugs' market cap and valuation?
As of 30 Oct 2026: market cap ₹3,973 Cr, P/E 20.6x, ROCE 12.0%, ROE 13.4%, dividend yield 0.46%.